MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Thomas Warner from Proactive after the Europe-based pharmaceutical company announced the delivery of the first doses of its CannEpil® units to patients in the United Kingdom.
Clements also discusses recent changes at boardroom level and looks ahead to what investors can expect from MGC during the next few months, saying that the company will "keep chipping away."